A consortium of leading Chinese pharmaceutical manufacturers, distributors, venture capital partners and e-commerce companies, Health Industry Innovation Alliance (HIIA), have announced that its members signed a memorandum of understanding to improve the pharmaceutical ecosystem domestically and throughout the Asia-Pacific region.

By fostering partnership, mutual trust, inclusiveness and shared success between players across the healthcare spectrum, HIIA members plan on building a better healthcare model that makes people healthier and happier.

Beijing Rogrand E-commerce Co. Ltd., Sinopharm Group Hubei Co. Ltd., Beijing Medi'care Ltd., Shenyang Sunshine Pharmaceutical Co., Guangzhou Baiyunshan Medicine Group Co., HG Captital Fund Management Co., AstraZeneca Pharmaceuticals (China) Co., Pfizer Investment Co., Ltd (China),  Xian-Janssen Pharmaceutical Ltd are the few member companies who took part in the signing of the memorandum.

The memorandum was signed as HIIA members prepare for the second Asia- Pacific Economic Coorporation (APEC) China Health Industry Forum, to be held in Beijing in December 2017.  HIIA was founded following the first APEC China Health Industry Forum in 2016.